Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anjali Babbar"'
Autor:
Yi Liu, Pingda Ren, Anjali Babbar, Sarah J. Firdaus, Jeffrey H. Chen, Tess Ely, Jun Feng, Jeff M. Kucharski, Yuching Chen, Linda V. Kessler, Ulf Peters, Rasmus Hansen, Lian-Sheng Li, Matthew R. Janes, Matthew P. Patricelli
Supplementary Table 1. Biochemical and Cell engagement SAR. Supplementary Table 2. Data collection and refinement statistics (Molecular replacement). Supplementary Table 3. Selectivity of ARS-853 across KRAS isoforms and GTP vs. GDP states. Supplemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb4c1da5f413c618429e4a216ba9b29
https://doi.org/10.1158/2159-8290.22531619
https://doi.org/10.1158/2159-8290.22531619
Autor:
Ulf Peters, Rasmus Hansen, Matthew R. Janes, Lian-Sheng Li, Patrick Parvis Zarrinkar, Anjali Babbar, Jun Feng, Yuching Chen, Pingda Ren, Yi Liu
Publikováno v:
Nature Structural & Molecular Biology. 25:454-462
Activating mutations in KRAS are among the most common tumor driver mutations. Until recently, KRAS had been considered undruggable with small molecules; the discovery of the covalent KRASG12C inhibitors ARS-853 and ARS-1620 has demonstrated that it
Autor:
Rasmus, Hansen, Ulf, Peters, Anjali, Babbar, Yuching, Chen, Jun, Feng, Matthew R, Janes, Lian-Sheng, Li, Pingda, Ren, Yi, Liu, Patrick P, Zarrinkar
Publikováno v:
Nature structuralmolecular biology. 25(6)
Activating mutations in KRAS are among the most common tumor driver mutations. Until recently, KRAS had been considered undruggable with small molecules; the discovery of the covalent KRAS
Autor:
Carol Thach, Jeff Kucharski, Jingchuan Zhang, Yvonne Yao, Shuangwei Li, Anjali Babbar, Dashyant Dhanak, Rasmus Hansen, Yuan Liu, Yuching Chen, Pingda Ren, Ulf Peters, Yi Liu, Shisheng Li, Ke Yu, Yi Wang, Patrick Parvis Zarrinkar, Xiaohu Deng, Matthew R. Janes, Sarah J. Firdaus, Ata Zarieh, Lian-Sheng Li, Tao Wu, Xin Guo, Jun Feng, Matthew V. Lorenzi, Dana D. Hu-Lowe, Jeffrey H. Chen
Publikováno v:
Cancer Research. 78:929-929
Activating mutations in KRAS have a high prevalence in human cancer. The codon 12 glycine to cysteine missense mutation (KRASG12C) is among the most common KRAS mutations, present in non-small cell lung adenocarcinoma (~15 %), colorectal adenocarcino
Autor:
Jeff Kucharski, Ulf Peters, Yun O. Long, Shisheng Li, Pingda Ren, Ata Zarieh, Dana D. Hu-Lowe, Ke Yu, Yuan Liu, Tao Wu, Carol Thach, Dirk Brehmer, Tess Ely, Xin Guo, Patrick P. Zarrinkar, Matthew P. Patricelli, Yi Wang, Rasmus Hansen, Dashyant Dhanak, Yi Liu, Jun Feng, Shuangwei Li, Matthew R. Janes, Yuching Chen, Sarah J. Firdaus, Levan Darjania, Linda Kessler, Jeffrey H. Chen, Xiaohu Deng, Yvonne Yao, Anjali Babbar, Matthew V. Lorenzi, Jingchuan Zhang, Lian-Sheng Li
Publikováno v:
Cell. 172:578-589.e17
KRASG12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active cycling of KRASG12C between its act